The dichotomy of results, claiming that serum IGF-1 is either lower or greater, or that increasing serum IGF-1 may or may not have an impact on patients, may suggest the existence of AD disease subtypes differing by serum IGF-1 level and response to supplementation. This evidence concerns the gene IGF1 and Alzheimer disease.